Director, Bioconjugation

Role Senior scientific leader as Director of Bioconjugation, focusing on antibody-drug conjugates (ADCs) and antibody-RNA conjugates (ARCs/AOCs). Objectives Defining bioconjugation strategies, leading a team of scientists, partnering across disciplines to advance conjugate therapeutics from target selection through candidate nomination and transition to development. Responsibilities Setting the bioconjugation platform strategy; overseeing chemistry, linker-payload design, and conjugation technology; managing external collaborations. Requirements PhD in chemistry, biochemistry, or related, with 8+ years in industry or academia, including at least 6 years in leadership roles. Deep expertise in bioconjugation chemistry—cysteine/lysine conjugation, site-specific and enzymatic methods, click chemistry—and experience with cytotoxic payloads, oligonucleotide conjugates, and degrader platforms. Proven track record in advancing discovery programs to clinical candidates, with strong analytical skills (RP-HPLC, SEC, LC-MS). Preferred qualifications Leadership in discovery project teams, oligonucleotide therapeutics, glycan-mediated platforms, and CMC/tech transfer experience supporting IND-enabling packages. High-value specifics Antibody conjugates, payload diversity (small molecules, oligonucleotides, degraders), therapeutic areas, and portfolio strategy. Collaboration Cross-functional with Discovery Chemistry, Biology, DMPK, Toxicology, and external partners. Work setup Location not explicitly specified, likely hybrid or onsite given the role's strategic leadership and collaboration scope. #J-18808-Ljbffr Bristol Myers Squibb